Light-Based Nasal Therapy Trial Completion Puts Ondine on Investors’ Radar

Ondine Biomedical, Inc. (GB:OBI) announced an update on their ongoing clinical study.

Ondine Biomedical Inc. has reported an update on its Canadian trial titled “A Group-Randomized, Standard-of-Care-Controlled, Crossover Trial Evaluating Nasal Antimicrobial Photodisinfection for the Prevention of Surgical Site Infections.” The study aims to see if a light-based nasal treatment can cut infection rates after major surgery, which could support broader use of this technology in hospitals.

The intervention is a nasal antimicrobial photodisinfection therapy, delivered via the Steriwave Nasal Photodisinfection System. The goal is to kill germs in the nose before surgery, using a quick light treatment instead of or in addition to existing prep methods.

The trial is an interventional study that randomly assigns hospital groups to either the new nasal light treatment or standard care, then crosses them over. There is no masking, and the main goal is prevention, so results focus on whether this practical approach lowers infection risk compared with current practice.

The study has a status of completed, with initial submission recorded on 11 September 2025 and the most recent update on 11 May 2026, signaling fresh reporting of data or protocol refinements. Primary and final completion dates are not fully detailed yet, but the latest update suggests the data set is mature and ready for analysis or publication.

If the trial shows lower surgical infection rates, it could support wider adoption of Ondine’s light-based system and improve visibility for the company among infection-control buyers. For investors, credible Phase 4 data in real-world hospital settings can drive re-rating, though competition from traditional antibiotic-based protocols and other device makers will likely keep expectations measured until peer-reviewed results are public.

The study remains listed as completed and recently updated, with further details available on the ClinicalTrials portal.

To learn more about GB:OBI’s potential, visit the Ondine Biomedical, Inc. drug pipeline page.